Nucala

Understanding Nucala® 

Nucala® (mepolizumab) is a monoclonal antibody therapy used to treat inflammatory diseases associated with high eosinophil levels. It works by targeting interleukin-5 (IL-5), a key protein involved in the production and survival of eosinophils, which contribute to inflammation in various conditions. By reducing eosinophil levels, Nucala® helps control symptoms and prevent disease flares in patients with eosinophilic-driven diseases.

How Nucala Works:

• Inhibits IL-5, reducing the production and survival of eosinophils.
• Lowers eosinophil levels, decreasing inflammation in affected tissues.
• Helps prevent disease flares and improve symptom control in eosinophilic-driven conditions.

FDA Approvals:

• Severe Eosinophilic Asthma: Approved on November 4, 2015
• Eosinophilic Granulomatosis with Polyangiitis (EGPA): Approved on December 12, 2017

For more information, please visit the Nucala patient website and speak with your healthcare provider to determine if Nucala® is the right treatment option for you.